Pathologies and Treatments

Diabetic retinopathy is currently the most common cause of vision loss of vascular origin. It is characterized by the deterioration of the blood vessels in the retina, which can manifest as fluid leakage and the appearance of diabetic macular edema and, in more severe cases, complete occlusion of the vessels, leading to severe retinal ischemia. In an attempt to improve circulation, new low-quality blood vessels (neovessels) are produced, which are responsible for the complications associated with what is known as proliferative diabetic retinopathy.

When a diabetic patient also presents other risk factors such as high blood pressure, obesity, high cholesterol, or smoking, the risk of developing ocular complications multiplies. For this reason, a patient suffering from diabetic retinopathy must be very disciplined in managing their overall health, diet, and weight control, and must avoid smoking. Even if no symptoms are present, the patient must undergo regular ophthalmological check-ups. Prevention and early diagnosis drastically improve the visual prognosis of the disease. Nowadays, in most patients, it is possible to avoid reaching extreme situations such as blindness.

In few diseases is the benefit of prevention so high.

Pregunta-li a ChatGPT

Symptoms

Many people with early diabetic retinopathy do not show symptoms, although they may progressively develop complications. For this reason, anyone with diabetes should undergo regular eye examinations to prevent avoidable complications in time.

Treatments

A complete ophthalmological examination is essential and should include the following tests: a retinography, an optical coherence tomography (OCT), fluorescein angiography—unless contraindicated due to allergy to fluorescein—and a visual field test.

It is likely that people in the earliest stages of non-proliferative diabetic retinopathy may not require treatment. Some patients affected by very mild diabetic macular edema without symptoms may only need regular monitoring of their eye condition. In other cases, intravitreal injections of anti-angiogenic drugs or slow-release corticosteroids, or a combination of both, are necessary to control the edema, restore vision, and prevent vision loss due to irreversible degenerative changes in the fine cellular layers of the retina. In very specific cases, laser photocoagulation near the macular area, selectively targeting microaneurysms, is advisable to reduce the edema.

When the disease shows signs of progressing to proliferative forms, extensive photocoagulation of areas lacking blood supply (ischemic zones) must be performed to prevent advancement to these high-risk stages for serious complications. Failing to carry out this treatment out of fear of the laser is a serious mistake that can lead to irreversible outcomes.

In advanced cases with intraocular hemorrhage and/or retinal detachment, advanced intraocular microsurgery techniques under local anesthesia are necessary. Laser treatment and various microsurgical techniques are highly effective in treating diabetic retinopathy and allow us to manage even the most severe cases. However, the ideal situation, thanks to proper prevention of complications, would be to avoid reaching this point.

Medicina regenerativa: Endoret

Con el tratamiento de medicina regenerativa Endoret propiciamos la reparación de la superficie ocular afectada por la sequedad ocular. Se trata de un plasma rico en factores de crecimiento para el tratamiento de las lesiones de la superficie ocular elaborado a partir de la sangre del mismo paciente. Con esta formulación individualizada se consigue una tolerancia completa y una efectividad óptima. Esta opción terapéutica revolucionaria es muy eficaz en casos de defectos epiteliales persistentes o úlceras corneales. Asimismo se puede aplicar después de una cirugía refractiva corneal, una cirugía ocular o en el Síndrome de Sjögren.

Procedures

Medicina regenerativa: Endoret

Con el tratamiento de medicina regenerativa Endoret propiciamos la reparación de la superficie ocular afectada por la sequedad ocular. Se trata de un plasma rico en factores de crecimiento para el tratamiento de las lesiones de la superficie ocular elaborado a partir de la sangre del mismo paciente. Con esta formulación individualizada se consigue una tolerancia completa y una efectividad óptima. Esta opción terapéutica revolucionaria es muy eficaz en casos de defectos epiteliales persistentes o úlceras corneales. Asimismo se puede aplicar después de una cirugía refractiva corneal, una cirugía ocular o en el Síndrome de Sjögren.

Dr. Jordi Monés,

M.D. PhD

Número de Col·legiat COMB: 22.838

Director. Doctor of Medicine and Surgery. Specialist in Ophthalmology. Specialist in Retina, Macula, and Vitreous.

If you found this interesting, feel free to share it here:

Last modified: 19/08/2025
Scroll to Top
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.